Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing proprietary product candidates to treat central nervous system diseases. The company's website is www.minervaneurosciences.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Minerva Neurosciences, Inc. does
In the company’s own words
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing proprietary product candidates to treat central nervous system diseases. The company's website is www.minervaneurosciences.com.
Minerva's lead product candidate is roluperidone, currently in development for treating negative symptoms in patients with schizophrenia. Roluperidone works by blocking serotonin 5-HT2A receptors, sigma-2 receptors, and alpha-adrenergic subtypes, mechanisms designed to address negative symptoms such as lack of motivation, inability to experience positive emotions, and diminished emotional expression without the side effects associated with existing antipsychotic therapies. In August 2022, the company submitted a New Drug Application to the FDA, which issued a Complete Response Letter in February 2024 requesting an additional Phase 3 confirmatory trial. The company is preparing to initiate the C19 trial in the second quarter of 2026, designed to enroll 380 patients with expected topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028.
Beyond schizophrenia, roluperidone is being explored for potential therapeutic applications in conditions including apathy in dementia, autism spectrum disorders, Alzheimer's disease, Parkinson's disease, and depression. The company has filed an Investigational New Drug application for apathy in dementia and received FDA clearance.
Minerva also holds rights to seltorexant, a selective orexin 2 receptor antagonist co-developed with Janssen for treating insomnia and major depressive disorder. In January 2021, the company sold its royalty rights to seltorexant to Royalty Pharma for sixty million dollars in upfront payment plus up to ninety-five million dollars in potential milestone payments.
The company has accumulated significant operating losses since inception and has not generated revenue from product sales or licensing. Minerva holds exclusive worldwide rights to roluperidone outside certain Asian countries through a license agreement with Tanabe Pharma Corporation. The company relies on third-party contract manufacturers for production and does not currently maintain internal manufacturing facilities.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BURLINGTON, MA
- Fiscal year end
- December
- CIK
- 1598646
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Minerva Neurosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Minerva Neurosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Minerva Neurosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Minerva Neurosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Minerva Neurosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”